

ORIGINAL ARTICLE

A relationship between the aldosterone–mineralocorticoid receptor pathway and alcohol drinking: preliminary translational findings across rats, monkeys and humans

EG Aoun¹, VA Jimenez^{2,3}, LF Vendruscolo^{4,10}, NAR Walter^{2,3}, E Barbier⁵, A Ferrulli⁶, CL Haass-Koffler^{7,8,9}, P Darakjian³, MR Lee⁹, G Addolorato⁶, M Heilig⁵, R Hitzemann³, GF Koob^{4,11}, KA Grant^{2,3} and L Leggio^{8,9}

Aldosterone regulates electrolyte and fluid homeostasis through binding to the mineralocorticoid receptors (MRs). Previous work provides evidence for a role of aldosterone in alcohol use disorders (AUDs). We tested the hypothesis that high functional activity of the mineralocorticoid endocrine pathway contributes to vulnerability for AUDs. In Study 1, we investigated the relationship between plasma aldosterone levels, ethanol self-administration and the expression of *CYP11B2* and MR (*NR3C2*) genes in the prefrontal cortex area (PFC) and central nucleus of the amygdala (CeA) in monkeys. Aldosterone significantly increased after 6- and 12-month ethanol self-administration. *NR3C2* expression in the CeA was negatively correlated to average ethanol intake during the 12 months. In Study 2, we measured *Nr3c2* mRNA levels in the PFC and CeA of dependent and nondependent rats and the correlates with ethanol drinking during acute withdrawal. Low *Nr3c2* expression levels in the CeA were significantly associated with increased anxiety-like behavior and compulsive-like drinking in dependent rats. In Study 3, the relationship between plasma aldosterone levels, alcohol drinking and craving was investigated in alcohol-dependent patients. Non-abstinent patients had significantly higher aldosterone levels than abstinent patients. Aldosterone levels positively correlated with the number of drinks consumed, craving and anxiety scores. These findings support a relationship between ethanol drinking and the aldosterone/MR pathway in three different species.

Molecular Psychiatry (2018) **23**, 1466–1473; doi:10.1038/mp.2017.97; published online 2 May 2017

INTRODUCTION

Several neuroendocrine pathways have been hypothesized to be involved in ethanol drinking and craving.¹ Among them, preliminary work suggests a role of aldosterone. Aldosterone, a steroid hormone of the mineralocorticoid family, is mainly produced by the zona glomerulosa of the adrenal cortex in the adrenal gland. Aldosterone production is largely controlled by regulation of the *CYP11B2* gene that encodes aldosterone synthase.^{2,3} Aldosterone, in turn, regulates electrolyte and fluid homeostasis through binding to mineralocorticoid receptors (MRs), which are encoded by the gene *NR3C2*. In the brain, aldosterone via MR signaling may have a role in anxiety and alcohol drinking. Particularly relevant, MRs are mainly expressed in limbic brain regions as the amygdala and the prefrontal cortex (PFC),^{4–6} two key brain areas involved in the development and maintenance of excessive ethanol consumption.⁷ Notably, the central nucleus of the amygdala (CeA) expresses MRs at greater levels compared with other amygdala nuclei.⁸ The CeA has an important role in anxiety, stress and stress-induced ethanol

drinking;⁹ alterations in its structure and function may result in disinhibition of downstream regions that regulate alcohol-related behaviors.^{10–12} The PFC has a critical role in addiction, including reinforcement learning, craving and inhibitory control.⁷ PFC neurons send projections to the CeA; changes in functional connectivity between PFC and CeA have been reported in individuals who are less able to cope with stressful events and alcohol-dependent individuals.^{11,13,14}

Plasma aldosterone levels increase in alcoholic patients during early alcohol withdrawal and normalize during recovery.¹⁵ This increase may contribute to clinically relevant hemodynamic changes during chronic alcohol use and withdrawal; indeed, there is a relationship between regulation of blood volume and ethanol drinking and craving.^{15–17} For example, we previously reported a significant positive correlation between aldosterone levels and both anxiety and obsessive craving in a pilot study with alcohol-dependent patients.¹⁸

Here, we investigated the hypothesis that the aldosterone/MR pathway contributes to the vulnerability for alcohol use disorders

¹Department of Psychiatry and Human Behavior, Brown University Medical School, Providence, RI, USA; ²Division of Neuroscience, Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR, USA; ³Department of Behavioral Neuroscience, Oregon Health and Science University, Portland, OR, USA; ⁴The Scripps Research Institute, La Jolla, CA, USA; ⁵Center for Social and Affective Neuroscience, IKE, Linköping University, Linköping, Sweden; ⁶Department of Internal Medicine, Catholic University of Rome, Rome, Italy; ⁷Center for Alcohol and Addiction Studies, Department of Psychiatry and Human Behavior, Brown University, Providence, RI, USA; ⁸Center for Alcohol and Addiction Studies, Department of Behavioral and Social Sciences, Brown University, Providence, RI, USA and ⁹Section on Clinical Psychoneuroendocrinology and Neuropsychopharmacology, National Institute on Alcohol Abuse and Alcoholism and National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD, USA. Correspondence: Dr L Leggio, Section on Clinical Psychoneuroendocrinology and Neuropsychopharmacology, National Institute on Alcohol Abuse and Alcoholism and National Institute on Drug Abuse, National Institutes of Health, 10 Center Drive (10CRC/15330) MSC 1108, Room 1-5429, Bethesda, MD 20892-1108, USA. E-mail: lorenzo.leggio@nih.gov

¹⁰Current address: National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD, USA.

¹¹Current address: National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Rockville, MD, USA.

Received 29 November 2016; revised 15 February 2017; accepted 16 March 2017; published online 2 May 2017




Figure 1. Study 1 in monkeys: Experimental timeline (a). All monkeys were trained during the baseline phase to participate in awake blood collection from the home cage and to operate an operant panel. Schedule-induced polydipsia began with a 1.5 g kg^{-1} volume equivalent of water, after which ethanol (4% (w v⁻¹)) was introduced and the daily dose increased each 30 days. Following ethanol induction, all animals had 22 h per day access to ethanol and water for ~14 months. Aldosterone was assayed from samples collected during baseline and after the first and second 6 months of self-administration as indicated by the arrows. Samples for blood ethanol concentration were collected throughout the experiment and are indicated by vertical lines. Plasma aldosterone levels before ethanol access (baseline), and following 6 and 12 months of voluntary ethanol self-administration (b). There was a significant effect of experimental phase ($F_{2,23} = 6.19$, $**P = 0.0071$). Tukey's *post hoc* comparisons revealed that aldosterone was significantly higher at both 6 months ($**P = 0.0075$) and 12 months ($**P = 0.0048$) of self-administration, but no differences were found between 6 and 12 months ($P = 0.99$). Results are expressed as $m \pm s.d.$

(AUDs) in studies of alcohol-related behaviors in macaques (Study 1), rats (Study 2) and humans (Study 3).

MATERIALS AND METHODS

Study 1

Setting. This study was conducted at the Oregon National Primate Research Center (ONPRC). All procedures adhered to the NIH Guide for the Care and Use of Laboratory Animals and were approved by the ONPRC IACUC.

Subjects. Subjects were male rhesus macaques (*Macaca mulatta*, $n = 13$), 4.5–5.5-year-old and from two cohorts (7a and 7b) of the ONPRC breeding colony (details in: <http://www.MATRR.com>). The monkeys were acclimated to the laboratory, established on an 11–13 light–dark cycle, and then extensively trained to comply with unanesthetized venipuncture. This procedure, taking samples from awake monkeys under calm conditions, was analogous to that used in the human protocol (Study 3). Monkeys were studied in a within-subject longitudinal design, and the animals were part of a larger study on adrenal response to ethanol self-administration.^{19,20}

Methods. Ethanol self-administration monkey model: Schedule-induced polydipsia, a form of adjunctive behavior where the scheduled delivery of small amounts of preferred food can induce large volumes of fluid intake, was used to establish rapid drinking without food deprivation.²¹ Monkeys were then induced to drink set doses of 4% (w v⁻¹) ethanol (0, 0.5, 1.0 and 1.5 g kg^{-1} per day) in 30-day epochs followed by access to concurrent ethanol and water for 22 h per day, 7 days per week for 14 months under a well-established protocol.^{21,22} The protocol consisted of: (1) 6 months of uninterrupted ethanol self-administration; followed by (2) 1 month of daily self-administration and four interspersed neuroimaging/pharmacological procedures (an imaging session and acute single doses of dexamethasone/ovine corticotropin-releasing factor/saline). The 6- and 1-month phases were then repeated to total 14 months. Self-administration was suspended only during the time it took for the procedures (~2 h on a single day) and there were at least three self-administration sessions between procedures. The neuroimaging/

pharmacological months were not included in the average self-administration data because of the abbreviated sessions and procedural effects. There was at least a 2-week period of uninterrupted ethanol self-administration before necropsy. Here, we present longitudinal data from pre-ethanol baseline, after both the first and the second self-administration 6-month blocks. Blood samples (20 μl) for blood ethanol concentration (BEC) were taken every 5–7 days, at 7 h after session onset (see Figure 1a for experimental timeline).

Necropsy: All monkeys were sent to necropsy at the end of the 14-month self-administration protocol, without experiencing abstinence using a detailed procedure for brain perfusion in ice-cold artificial central spinal fluid, brain excision, dissection and freezing in liquid nitrogen, maintaining the tissue at -80°C until RNA was extracted.²³

Gene expression from RNAseq: Tissue samples were collected at necropsy from the PFC (area 32) and CeA for RNAseq analyses. These brain areas from the 13 monkeys described above were part of a larger group of samples used for full RNAseq gene expression analyses; the RNAseq methods and full results are detailed in Iancu *et al.* (GEO accession ID: GSE84332).²⁴ Here we specifically assessed the correlation of normalized gene expression counts of two key enzymes (*NR3C2* and *CYP11B2*) and a control gene (*ACTB*) with ethanol consumption in the same 13 monkeys (cohorts 7a and 7b) that underwent the ethanol self-administration protocol and were also assayed for plasma aldosterone levels.

Study 2

Setting. This study was conducted at The Scripps Research Institute. All procedures adhered to the NIH Guide for the Care and Use of Laboratory Animals and were approved by the The Scripps Research Institute IACUC.

Subjects. Adult male Wistar rats ($n = 34$; Charles River, Raleigh, NC, USA), weighing 225–275 g at the beginning of the experiments, were housed in groups of 2–3 per cage in a temperature-controlled (22°C) vivarium on a 12–12 light–dark cycle (lights on at 2000 hour). All behavioral tests were conducted during the dark phase of the cycle. Animals had *ad libitum* access to food and water.

Methods. The experimental timeline is shown in Figure 3. Rats were tested in the elevated plus maze before any exposure to ethanol to measure baseline anxiety-like behavior. The averages \pm s.e.m. for % time in the open arms (an index of anxiety-like behavior) were as follows: 28.2 ± 5.5 and 22.0 ± 4.1 , for the dependent and nondependent groups, respectively. The rats were then trained in daily 30-min sessions to lever press for access to ethanol (10% (w v⁻¹), 0.1 ml per delivery) under a fixed-ratio 1 (FR1) schedule of reinforcement). The rats were assigned to two groups matched in terms of ethanol responding. The dependent ($n = 16$) group was chronically exposed to daily cycles of ethanol intoxication (14 h vapor ON; target BEC: 200 mg dl^{-1}) and withdrawal (10 h vapor OFF), the nondependent ($n = 18$) group was exposed to air without ethanol.

The dependent and nondependent rats were tested for ethanol intake in 30-min sessions where ethanol and water (0.1 ml) were concurrently available according to FR1 schedules. These sessions coincided with the peak of acute withdrawal in the dependent group (6–8 after alcohol vapor turned off), when BECs were negligible. Based on previous studies, the responding levels observed during FR1 operant sessions would be expected to yield BECs below 50 mg dl^{-1} in nondependent rats and above 100 mg dl^{-1} in dependent rats.²⁵ We also measured motivation for ethanol using a progressive ratio (PR) schedule, during which the number of lever presses required to obtain reinforcement increases progressively with each completed ratio. Finally, to measure the persistence to ethanol drinking despite punishment (used herein as an index of compulsive-like drinking), we adulterated the ethanol solution with increasing concentrations of quinine (5, 10, 25 and 50 mg l^{-1} ; between-session design), which is bitter and aversive to rats. We observed that dependent rats displayed increased ethanol intake (FR1), motivation for ethanol (PR) and compulsive-like drinking compared with nondependent rats (for all behavioral data see Vendruscolo *et al.*²⁵).

At the end of the behavioral experiments, we collected rats' brains during acute withdrawal (24 h post vapor) and measured *Nr3c2* mRNA levels in the PFC and CeA using a nuclease protection array. We did not observe overall significant alterations in *Nr3c2* mRNA levels between dependent and nondependent rats.²⁶ In the present study, we reanalyzed the behavioral data and *Nr3c2* mRNA data from our previous work²⁶ using a novel statistical approach. The results of this analysis are new and have not been published previously.

Study 3

Setting. This study was conducted at the *Alcoholism Treatment Unit*, Institute of Internal Medicine, Catholic University, Rome (Italy). The study was approved by the local Ethics Committee and performed according to the Declaration of Helsinki. Participants signed an informed consent before participation.

Subjects. Participants were part of the *Psychoneuroendocrinology Project*, which aimed to explore secondary endocrine-related outcomes from patients who participated in the *Baclofen Intervention Study* (EudraCT: 2006-000713-37); details of the parent study have been reported elsewhere.²⁷ Briefly, out of 94 patients screened for inclusionary/exclusionary criteria (Supplementary Table S1), 42 alcohol-dependent patients were enrolled and 37 completed the 12-week study. For demographics and baseline characteristics, see Supplementary Table S2. During the study, all patients received: (1) study medication tablets (either baclofen or placebo in a double-blind randomized manner); although no baclofen effect was found on the primary drinking outcomes,^{27,28} nor on blood aldosterone levels (data not shown), the medication condition was included as a covariate; and 2) psychological therapy provided by trained staff (BRENDA²⁹) at each outpatient visit for nine sessions of ~30 min each.²⁷ Participants were also encouraged to attend Alcoholics Anonymous.

Methods. Alcohol drinking: At the screening visit (Week-00), patients were asked to abstain from alcohol at least 3 days before enrollment at the subsequent visit (Week-01). Patients were monitored daily between Week-00 and Week-01 visits. Patients with significant withdrawal symptoms were treated with benzodiazepines; patients who required >10 days of benzodiazepines treatment were excluded. Thus, all patients (N=42) started the study after at least 3 and no >10 days of alcohol abstinence. No benzodiazepines were administered at any other point in the study. The number of standard alcohol drinks consumed over the 28 days preceding the screening visit and between visits was recorded using the Timeline Follow-Back method³⁰ and further corroborated by BEC and liver enzymes (as blood biomarkers of alcohol use) at each visit.

Alcohol craving: The obsessive-compulsive disorder scale was used to measure alcohol craving (obsessive-compulsive disorder scale total score), including the obsessive disorder subscale (ODS) and compulsive disorder subscale (CDS).^{31,32}

Anxiety: The State and Trait Inventory (STAI) test was used to assess state anxiety.³³

For assays and statistical analysis in Studies 1–3 see Supplementary Information.

RESULTS

Study 1

Ethanol self-administration and plasma aldosterone in monkeys. Similar to other studies using this ONPRC rhesus population and ethanol self-administration protocol, there was a wide range of

average daily ethanol intakes.²² As detailed above, the drinking data are divided experimentally with the first 6 months of uninterrupted 22 h per day access treated as one block and the second 6 months of uninterrupted 22 h per day access as a second block.¹⁹

Average (m ± s.e.m.) daily intakes for the first 6-month block was 2.04 ± 0.2 g kg⁻¹ per day and ranged from 1.2 to 3.3 g kg⁻¹ per day. Average daily intakes for the first second month block was 2.7 ± 0.2 g kg⁻¹ per day and ranged from 1.4 to 3.7 g kg⁻¹ per day. Overall, 12-month daily ethanol intake averaged 2.35 ± 0.16 g kg⁻¹. Similarly, BECs collected at 7 h after the daily session produced great individual variations. Average BEC (m ± s.e.m.) through the first 6-month block (35 samples per monkey) was 46 ± 7 mg dl⁻¹ and ranged from 9 to 87 mg dl⁻¹. Average BEC through the second 6-month block (26 samples per monkey) was 78 ± 9 mg dl⁻¹ and range was 21–134 mg dl⁻¹.

Aldosterone (m ± s.d.) increased from a baseline of 94 ± 63 to 114 ± 45 pg ml⁻¹ after 6-month self-administration and 116 ± 50 pg ml⁻¹ after 12-month self-administration. This finding represented a significant effect of experimental phase (F_{2,23} = 6.19, P = 0.0071). Tukey's *post hoc* comparisons revealed that aldosterone was significantly higher at both 6 months (P = 0.0075) and 12 months (P = 0.0048) of self-administration, but no differences were found between 6 months and 12 months (P = 0.99) (Figure 1b). Aldosterone at 6- or 12-month time point did not correlate with average ethanol intake (g kg⁻¹ per day) or average BEC (mg dl⁻¹), but rather appeared to be an effect of chronically drinking at least an average of 1.2 g kg⁻¹ per day (i.e., the average intake for the lowest drinking monkey).

Water and total (water+ethanol) fluid intake also showed a wide range of individual differences. As reported previously,²⁰ no relationship was found between ethanol or water intake. Over the first 6 months, the average water and total intakes were 945 ± 104 and 1356 ± 119 ml per day, respectively. Similar volumes were recorded during the second 6 months of self-administration, 913 ± 115 and 1496 ± 146 ml per day for water and total fluid, respectively. Total average daily fluid consumption across the entire self-administration ranged from 937 ± 100 ml per day water and 1409 ± 125 ml per day total intake. There was no correlation with aldosterone levels at either 6-month block or with average water consumption over the entire 12 months of ethanol self-administration (all r² values < 0.07, P-values > 0.41).

Post-mortem gene expression in monkey brain. Using a subset (n = 13 monkeys analyzed in this manuscript) of an existing set of next-generation sequencing project in this monkey model of alcohol self-administration (GEO accession ID: GSE84332), we




Figure 2. Study 1 in monkeys: Correlations between average ethanol intake (g kg⁻¹ per day) and the mineralocorticoid nuclear receptor gene *NR3C2* expression in the central nucleus of the amygdala (a and b) in rhesus macaques. Ethanol intake is shown as an average during the second 6 months block (a) and over the entire 12 months period (b) of ethanol self-administration. There was a significant correlation between the expression of *NR3C2* in the CeA and ethanol intake at both the second block of 6 months (a; r² = 0.48; P = 0.008) and the overall 12 months (b; r² = 0.33; P = 0.042).




Figure 3. Study 2 in rats: experiment timeline (top panel) and behavioral findings in dependent and nondependent rats based on *Nr3c2* expression levels in the central nucleus of the amygdala (CeA) and prefrontal cortex (PFC). *Top panel:* The rats were tested in the elevated plus maze before any exposure to ethanol to measure baseline anxiety-like behavior. The same rats were then trained in daily 30-min sessions to lever press for access to ethanol (10% (w v⁻¹), 0.1 ml per delivery), and assigned to two groups: dependent ($n = 16$; chronically exposed to ethanol vapor) and nondependent ($n = 18$; exposed to air without ethanol) rats. They were tested under a fixed-ratio 1 (FR1) schedule of reinforcement to measure 'intake,' a progressive ratio (PR) schedule to measure 'motivation' for ethanol and tested for the persistence to drink ethanol adulterated with quinine (used herein as an index of 'compulsive drinking'). At the end of the behavioral experiments, we measured *Nr3c2* mRNA levels in the PFC and CeA. *Bottom panel:* The behavior and *Nr3c2* mRNA levels data have been published previously.²⁶ Here, we present a new statistical analysis that has not been published previously. A PCA revealed the occurrence of two main factors for each dependent and nondependent group that were interpreted to reflect 'intake/motivation' and 'anxiety/compulsive drinking' (a and d; see Supplementary Figure S1 for additional results). The *Nr3c2* expression levels in the CeA were significantly correlated with 'anxiety/compulsive drinking' in dependent rats (b) but not in nondependent rats (e). No significant correlations were found for the PFC data for either dependent (c) or nondependent (f) rats. Ethanol drinking tests and *Nr3c2* level measurements were conducted during acute alcohol withdrawal in the dependent rats.

found that *NR3C2* was expressed in both PFC and CeA. Ethanol intake was negatively correlated with the expression of *NR3C2* in the CeA, in both the second 6 months of drinking and over the entire 12 months of drinking (Figures 2a and b), but there was no significant correlation with the first 6 months of drinking (data not shown). Specifically, there was a stronger correlation to the intake over the second block of 6 months of drinking ($n = 13$, $r^2 = 0.48$; $P = 0.008$; Figure 2a) than over the entire 12-month period ($n = 13$, $r^2 = 0.33$; $P = 0.042$; Figure 2b). In contrast, the expression of *NR3C2* in PFC was not correlated with ethanol intake at either the first block of 6 months, the second block of 6 months (time point closer to necropsy) or with ethanol intake over all 12 months (data not shown). The *CYP11B2* gene was not expressed above detectable levels in either brain area. For reference, there was no correlation between ethanol intake and expression of *ACTB* (a common housekeeping or reference gene) at the second block of 6 months ($r^2 = 0.001$; $P = 0.92$) nor at the overall 12 months ($r^2 = 0.038$; $P = 0.52$) (data not shown).

Study 2

The PCA including measures of anxiety-like behavior (% time in the open arms of the elevated plus maze), ethanol intake (FR1), motivation for ethanol (PR) and compulsive-like ethanol intake (quinine adulteration) revealed the occurrence of two factors in each group that together accounted for 70–76% of the variance in behavior. The examination of factor loadings was interpreted to reflect two independent behavioral constructs: (1) 'intake/motivation' and (2) 'anxiety/compulsive drinking'. These factors independently accounted for comparable amounts of the behavioral variance, indicating that the 'anxiety/compulsive drinking' factor (39.7% for dependent; 38.5% for nondependent) is nearly as important as the 'intake/motivation' factor (32.1% for dependent; 38.3% for nondependent) in explaining the observed behavioral differences. Additional analyses indicated that ethanol intake and the motivation for ethanol consumption reflected the same underlying behavioral construct for both dependent and non-dependent rats, that is, rats that exhibited an increase in ethanol intake under FR1 were the same animals that were more

motivated for ethanol under PR. Moreover, antecedent anxiety-like behavior (i.e., before any ethanol exposure) predicted compulsive-like ethanol drinking specifically in dependent rats (see Supplementary Information and Supplementary Figure S1).

The behaviors described above captured different aspects of ethanol dependence and provide a rationale for studying the relationship of *Nr3c2* levels with 'intake/motivation' and 'anxiety/compulsive drinking'. Pearson's test indicated a significant correlation between 'anxiety/compulsive drinking' PCA scores and *Nr3c2* expression levels in the CeA for dependent ($r^2=0.656$; $P<0.005$; Figure 3b) but not nondependent ($r^2=0.185$; $P=0.085$) rats (Figure 3e). No significant correlations were found between PCA scores and *Nr3c2* expression levels in the PFC for dependent ($r^2=0.0002$; $P=0.962$; Figure 3c) or nondependent ($r^2=0.185$; $P=0.085$; Figure 3c) rats.

Additional analyses indicated that the dependent rats that had increased levels of *Nr3c2* mRNA in the CeA displayed a trend toward exhibiting lower levels of antecedent anxiety-like behavior and, more importantly, exhibited lower levels of compulsive-like ethanol drinking after the development of dependence (Supplementary Figure S2).

Study 3

Effect of abstinent versus non-abstinent status on aldosterone levels. There was no significant difference in baseline (Week-00) average ($m \pm s.e.m.$) aldosterone levels between the abstinent ($233 \pm 58 \text{ pg ml}^{-1}$) and non-abstinent human subjects ($175 \pm 22 \text{ pg ml}^{-1}$). However, at Week-12, patients who did not maintain abstinence had significantly higher aldosterone levels ($232 \pm 57 \text{ pg ml}^{-1}$) compared with abstinent patients ($134 \pm 13 \text{ pg ml}^{-1}$) ($F_{1,213}=4.53$, $P=0.047$) (Figure 4). There was also a significant positive correlation between plasma aldosterone levels at Week-12 and the number of drinks consumed during the 12-week study period ($r^2=0.38$, $P=0.0007$).

Relationship between aldosterone levels and craving scales. At Week-00, no significant correlations were found between aldosterone and craving scales. At Week-12, there was a significant positive correlation between aldosterone levels and the craving scales examined, obsessive-compulsive disorder scale ($r^2=0.21$, $P=0.02$; Figure 5a), the obsessive ODS subscale ($r^2=0.19$, $P=0.02$;




Figure 4. Study 3 in humans: Plasma aldosterone levels at Week-12 in abstinent versus non-abstinent alcohol-dependent patients. Patients who did not maintain abstinence had significantly higher aldosterone levels compared with abstinent patients ($F_{1,213}=4.53$, $*P=0.047$). Results are expressed as $m \pm s.e.m.$

Figure 5b) and the compulsive CDS subscale ($r^2=0.19$, $P=0.02$; Figure 5c).

Relationship between aldosterone levels and anxiety scales. At Week-00, no significant correlations were found between aldosterone and the anxiety scales. At Week-12, a significant positive correlation was found between aldosterone levels and state anxiety (STAI-Y1) levels ($r^2=0.19$, $P=0.03$; Figure 5d).

DISCUSSION

The present set of findings support a link between the aldosterone/MR endocrine pathway and ethanol drinking. Notably, converging observations were obtained in three different species, that is, a monkey model of ethanol self-administration, a rat model of alcohol dependence and compulsive-like drinking, and humans with alcohol dependence.

In the monkey study, plasma aldosterone levels were significantly higher after 6 and 12 months of ethanol self-administration compared with baseline. This within-subjects comparison suggests that aldosterone increased as a consequence of ethanol consumption. Indeed, while the identification of a specific threshold remains for future work (e.g., by using monkeys that drank $<1.2 \text{ g kg}^{-1}$ per day), the data suggest that chronic drinking of at least an average of 1.2 g kg^{-1} per day, roughly equivalent to 5 drinks per day in humans, is sufficient to raise circulating aldosterone. The increase in aldosterone seen in the monkeys at 6 months remained high after 12 months of continued drinking, and did not increase further. These data suggest that aldosterone levels become regulated at a new set-point under daily ethanol consumption, consistent with the hypothesis that chronic ethanol produces an allostatic shift of brain stress systems.³⁴ The monkey study also indicated a specific relationship with ethanol drinking, as no significant correlations were observed with water intake.

In the rat study, we found that *Nr3c2* levels in the CeA, but not PFC, were correlated with anxiety-like behavior and compulsive-like alcohol drinking specifically in dependent rats. The dependent rats with high levels of *Nr3c2* in the CeA exhibited a trend to be less anxious-like when tested in the elevated plus maze before alcohol exposure. These same dependent rats with high levels of *Nr3c2* in the CeA exhibited less compulsive-like alcohol drinking compared with dependent rats with low levels of *Nr3c2*. This suggests that anxiety-like behavior prospectively predicted compulsive-like drinking in dependent rats, i.e.: the more anxious-like rats showed more compulsive-like ethanol drinking (drinking more despite the aversive bitter taste of quinine). Moreover, baseline anxiety-like behavior may be a marker of *Nr3c2* plasticity in alcohol dependence. These findings suggest that high *Nr3c2* levels in the CeA may be protective against compulsive ethanol drinking or, conversely, that low levels of *Nr3c2* expression may convey vulnerability for anxiety-related compulsive ethanol drinking. However, our experimental design prohibits a conclusion regarding gene expression differences as a response to drinking or a predisposition to drinking patterns or a response to alcohol withdrawal. It is important to note that both behavioral testing and brain collection for gene expression analysis were conducted during acute ethanol withdrawal, when blood ethanol levels were negligible.

In the human study, a between-subjects comparison indicated that aldosterone levels were significantly higher in alcohol-dependent patients who were drinking during the 12-week period, compared with those who maintained abstinence during the same time frame. The human data were further corroborated by the observation that aldosterone levels correlated with the amount of ethanol consumed during the 12-week period, that is, higher drinking levels were associated with higher plasma aldosterone levels.




Figure 5. Study 3 in humans: Correlations between plasma aldosterone levels at Week-12 and alcohol craving scores in alcohol-dependent patients. There were significant positive correlations between plasma aldosterone levels and the craving scales examined, that is, obsessive-compulsive drinking scale (OCDS) total score ($r^2 = 0.21$, $P = 0.02$) (a); the obsessive ODS subscale ($r^2 = 0.19$, $P = 0.02$) (b); and the compulsive CDS subscale ($r^2 = 0.19$, $P = 0.02$) (c). Correlation between plasma aldosterone levels at Week-12 and state anxiety measured by the State and Trait Inventory (STAI) Y1 scale in alcohol-dependent patients. There was a significant positive correlation between plasma aldosterone levels and state anxiety levels ($r^2 = 0.19$, $P = 0.03$) (d).

Taken together, the results suggest that inquiries into circulating aldosterone levels must look at both synthesis and receptor regulation. Post-mortem brain analysis from the monkeys, exploring the effects of aldosterone signaling on brain gene expression of aldosterone synthase (*CYP11B2*) and the mineralocorticoid nuclear receptor (*NR3C2*) genes, sheds some light on brain adaptation to the elevated aldosterone levels associated with ethanol consumption. Albeit preliminary, these findings suggest that *NR3C2* gene expression is sensitive to ethanol consumption in the CeA, but not in the PFC. The CeA is known to have key roles in modulating the effects of ethanol^{10–12,35} and the current data provide information suggestive of a potential selective role of aldosterone signaling in specific brain areas and pathways. Notably, the correlations with ethanol intake in the monkey are negative, with higher ethanol consumption predicting lower CeA *NR3C2* gene expression. One possibility is that blood aldosterone may be a peripheral marker of central MR activity, that is, increased peripheral aldosterone levels are a consequence of reduced MR-mediated negative feedback; alternatively, it may be that amygdalar MRs are downregulated as a compensatory effect of ethanol-induced increases in aldosterone. A third possibility is that peripheral aldosterone may be a proxy of central aldosterone synthesis; however, this latter hypothesis is unlikely. In fact, the *CYP11B2* gene has been detected in the rat brain only at very low levels^{36–38} and its function in the brain is unclear.² In our monkey study, the *CYP11B2* gene was not expressed at detectable levels in either the CeA or the PFC, hence there is no evidence of aldosterone synthesis in these brain areas. Finally, changes in DNA methylation and/or microRNA may represent additional putative mechanisms of how alcohol influences *NR3C2* gene expression, as shown for the regulation of MRs³⁹ and volume-regulating hormones.⁴⁰ Because the CeA is an important area for anxiety,

stress sensitization and stress-induced ethanol drinking,⁹ it is possible that aldosterone might be relevant to negative reinforcement processes associated with the addiction cycle. In support of this hypothesis, our previous,¹⁸ and the present human data, indicated a positive relationship between aldosterone levels and alcohol craving, as well as aldosterone levels and anxiety. The present rat study corroborates these clinical studies. Taken together, our findings across rats and humans support a role of the aldosterone/MR pathway in anxiety and ethanol drinking in AUD.

It is important to note that cortisol has a greater affinity for MRs than for glucocorticoid receptors. An added factor in the MR regulation is the interplay between aldosterone and cortisol. In general, aldosterone may modulate other stress-related neuropeptides (e.g., corticotropin-releasing factor, dynorphin- κ opioid systems, norepinephrine) in the extended amygdala that are known to drive a negative emotional state and excessive alcohol drinking.⁹ Activation of the hypothalamic-pituitary-adrenal axis characterizes initial alcohol use (binge/intoxication stage), but as dependence develops, hypothalamic-pituitary-adrenal axis activity is blunted and activation of extrahypothalamic brain stress systems characterize the withdrawal/negative-affect stage and protracted abstinence in the preoccupation/anticipation stage.⁹ Among these changes accompanying the activation of these stress systems, one may include an amygdalar MR downregulation, which in turn results in increased stress, anxiety and compulsive-like ethanol drinking. Future preclinical and human studies could test pharmacological approaches targeting the aldosterone/MR signaling towards developing novel medications for AUD.

The results presented here converge on the importance of aldosterone in alcohol-seeking behaviors via MR signaling.

Previous work indicated lower plasma sodium levels in patients in early alcohol withdrawal¹⁵ and increased concentration of fluid and salt-preserving hormones, like aldosterone, during early alcohol withdrawal and subsequent decrease after abstinence.^{41–46} However, our monkey and human studies were not conducted during acute withdrawal, only the rat study was. Both sodium and mean corpuscular volume (an indirect measure of osmolality) in Study 1 and Study 3 were in the normal range (data not shown), suggesting that peripheral aldosterone signaling at these time points was unlikely to contribute to alcohol-seeking behaviors. Obviously, peripheral actions of aldosterone may still be of relevance for engaging the MR system dysregulations (see above), and for other pathophysiological effects related to excessive alcohol use, such as alcohol-associated hypertension. Future work on this area could include hemodynamic studies and *NR3C2* gene expression analysis of the adrenocortical cortex tissue.

Study strengths include: (1) the potential role of the aldosterone/MR pathway in alcohol-seeking behaviors has been understudied; (2) the investigation was carried out across monkeys, rats and humans, thus providing cross-species and translational validation; and (3) this investigation used a well-validated non-human primate model of alcohol use; a well-validated and reliable rat model of alcohol dependence;^{47,48} and a clinically relevant sample of treatment-seeking alcohol-dependent patients. Limitations include: (1) the small sample sizes, although the size of the monkey sample was consistent with previous work^{49–51} and the human sample was relatively larger compared with our previous clinical study;¹⁸ (2) the different designs, given that the three studies were not planned *a priori* to be conducted in parallel. This aspect, together with species differences, different methodologies and the small sample size of Study 1 may explain some cross-species differences like the lack of correlation between plasma aldosterone and alcohol drinking in monkeys, which was the case with human subjects; (3) the exploratory nature of some analyses in Study 3, where, consistent with previous recommendations,^{52–54} statistical adjustment was not conducted; (4) the present data show correlations, but do not establish causality; therefore, future translational work is needed before drawing final conclusions; (5) unlike in monkeys and rats where the amount of alcohol consumption was observed, in humans alcohol intake was self-reported; we used BEC and liver enzymes to corroborate these self-reported data; however, additional objective measurements (e.g., carbohydrate-deficient transferrin, ethylglucuronide) were not included; and (6) we only assessed aldosterone in the morning; aldosterone secretion is highest in the morning and lowers during the afternoon and evening;⁵⁵ therefore, future studies may consider serial aldosterone determinations to account for the circadian rhythm. In spite of these limitations, this set of data provides novel and important information and cross-species translation on the potential role of the aldosterone/MR pathway in AUD.

In conclusion, the present findings in monkeys, rats and humans provide support for a relationship between alcohol drinking and the aldosterone/MR pathway in the context of excessive alcohol use. This study provides compelling evidence that this endocrine pathway should be further investigated as a putative target for the development of new pharmacotherapies for AUD.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGMENTS

We thank the following funding sources: European Foundation for Alcohol Research (ERAB) Grant EA0619 (to LL, GA) and ERAB exchange award EXA0802 (to LL); National Institutes of Health (NIH) intramural funding ZIA-AA000218 (Section on Clinical

Psychoneuroendocrinology and Neuropsychopharmacology; to LL), jointly supported by the Division of Intramural Clinical and Biological Research of the National Institute on Alcohol Abuse and Alcoholism (NIAAA) and the Intramural Research Program of the National Institute on Drug Abuse (NIDA); National Institute of Mental Health Grant MH101076 (research protected time for EGA under R25 mechanism); the Swedish Research Council (BE, MH); the Pearson Center for Alcoholism and Addiction Research (to LJV, GFK); and NIAAA Grants AA023867 (to CLH-K), AA010760 (to RH), AA08459 (to LJV, GFK) and AA109431 (to KAG). We also thank Karen Smith (NIH Library) for bibliographic assistance, Lisa Farinelli (Section on Clinical Psychoneuroendocrinology and Neuropsychopharmacology, National Institute on Alcohol Abuse and Alcoholism and National Institute on Drug Abuse) for providing support with the preparation of the manuscript and Dr Christa Helms for initial data organization.

AUTHOR CONTRIBUTIONS

LL and GA designed the human study; KAG designed the non-human primate study; RH designed the next-generation RNA sequencing study; LJV, EB, MH and GFK designed the rat study. LL, GA, MH, RH, GFK and KAG provided funding used to conduct the studies. LL, AF and GA conducted the human study, including collection of the clinical research data and patient care. EGA conducted the analyses of the human study. VAJ conducted the analysis of the non-human primate study. PD generated and NARW analyzed the gene expression data of the non-human primate study. LJV and EB conducted the experiments of the rat study; LJV, EB, MH and GFK analyzed the data of the rat study. EGA, VAJ, LJV, NARW, EB, CLH-K, MRL, GA, MH, GFK, KAG and LL participated in the interpretation of data for important intellectual contents. EGA and LL wrote the first draft of the manuscript. VAJ, LJV, NARW, EB, CLH-K, MRL, GA, MH, GFK and KAG contributed to the writing of the manuscript. All authors approved the final version of the manuscript.

REFERENCES

- 1 Kenna GA, Swift RM, Hillemecher T, Leggio L. The relationship of appetitive, reproductive and posterior pituitary hormones to alcoholism and craving in humans. *Neuropsychol Rev* 2012; **22**: 211–228.
- 2 Bureik M, Lisurek M, Bernhardt R. The human steroid hydroxylases CYP1B1 and CYP11B2. *Biol Chem* 2002; **383**: 1537–1551.
- 3 Hargovan M, Ferro A. Aldosterone synthase inhibitors in hypertension: current status and future possibilities. *JRSM Cardiovasc Dis* 2014; **3**:2048004014522440. (eCollection).
- 4 Mitra R, Ferguson D, Sapolsky RM. Mineralocorticoid receptor overexpression in basolateral amygdala reduces corticosterone secretion and anxiety. *Biol Psychiatry* 2009; **66**: 686–690.
- 5 Kruk MR, Haller J, Meelis W, de Kloet ER. Mineralocorticoid receptor blockade during a rat's first violent encounter inhibits its subsequent propensity for violence. *Behav Neurosci* 2013; **127**: 505–514.
- 6 Wingenfeld K, Kuehl LK, Dziobek I, Roepke S, Otte C, Hinkelmann K. Effects of mineralocorticoid receptor blockade on empathy in patients with major depressive disorder. *Cogn Affect Behav Neurosci* 2016; **16**: 902–910.
- 7 Edwards S, Koob GF. Neurobiology of dysregulated motivational systems in drug addiction. *Fut Neurol* 2010; **5**: 393–401.
- 8 Reul JM, de Kloet ER. Two receptor systems for corticosterone in rat brain: micro-distribution and differential occupation. *Endocrinology* 1985; **117**: 2505–2511.
- 9 Koob GF. The dark side of emotion: the addiction perspective. *Eur J Pharmacol* 2015; **753**: 73–87.
- 10 Dhaher R, Finn D, Snelling C, Hitzemann R. Lesions of the extended amygdala in C57BL/6J mice do not block the intermittent ethanol vapor-induced increase in ethanol consumption. *Alcohol Clin Exp Res* 2008; **32**: 197–208.
- 11 Gilpin NW, Herman MA, Roberto M. The central amygdala as an integrative hub for anxiety and alcohol use disorders. *Biol Psychiatry* 2015; **77**: 859–869.
- 12 Roberto M, Gilpin NW, Siggins GR. The central amygdala and alcohol: role of γ -aminobutyric acid, glutamate, and neuropeptides. *Cold Spring Harb Perspect Med* 2012; **2**: a012195–a012195.
- 13 Koob GF, Volkow ND. Neurobiology of addiction: a neurocircuitry analysis. *Lancet Psychiatry* 2016; **3**: 760–773.
- 14 Sinha R, Lacadie CM, Constable RT, Seo D. Dynamic neural activity during stress signals resilient coping. *Proc Natl Acad Sci USA* 2016; **113**: 8837–8842.
- 15 Kovács GL. The role of atrial natriuretic peptide in alcohol withdrawal: a peripheral indicator and central modulator? *Eur J Pharmacol* 2000; **405**: 103–112.
- 16 Doring WKH, Herzenstiel M-NI, Krampe H, Jahn H, Pralle L, Sieg S et al. Persistent alterations of vasopressin and N-terminal proatrial natriuretic peptide plasma levels in long-term abstinent alcoholics. *Alcohol Clin Exp Res* 2003; **27**: 849–861.

- 17 Hillemecher T. Volume intake and craving in alcohol withdrawal. *Alcohol Alcohol* 2006; **41**: 61–65.
- 18 Leggio L, Ferrulli A, Cardone S, Miceli A, Kenna GA, Gasbarrini G *et al*. Renin and aldosterone but not the natriuretic peptide correlate with obsessive craving in medium-term abstinent alcohol-dependent patients: a longitudinal study. *Alcohol* 2008; **42**: 375–381.
- 19 Helms CM, Park B, Grant KA. Adrenal steroid hormones and ethanol self-administration in male rhesus macaques. *Psychopharmacology (Berl)* 2014; **231**: 3425–3436.
- 20 Helms CM, Rau A, Shaw J, Stull C, Gonzales SW, Grant KA. The effects of age at the onset of drinking to intoxication and chronic ethanol self-administration in male rhesus macaques. *Psychopharmacology (Berl)* 2014; **231**: 1853–1861.
- 21 Grant KA, Leng X, Green HL, Szeliga KT, Rogers LSM, Gonzales SW. Drinking typography established by scheduled induction predicts chronic heavy drinking in a monkey model of ethanol self-administration. *Alcohol Clin Exp Res* 2008; **32**: 1824–1838.
- 22 Baker EJ, Farro J, Gonzales S, Helms C, Grant KA. Chronic alcohol self-administration in monkeys shows long-term quantity/frequency categorical stability. *Alcohol Clin Exp Res* 2014; **38**: 2835–2843.
- 23 Daunais JB, Davenport AT, Helms CM, Gonzales SW, Hemby SE, Friedman DP *et al*. Monkey alcohol tissue research resource: banking tissues for alcohol research. *Alcohol Clin Exp Res* 2014; **38**: 1973–1981.
- 24 Iancu OD, Colville A, Walter NA, Darakjian P, Oberbeck DL, Daunais JB *et al*. On the relationships in rhesus macaques between chronic ethanol consumption and the brain transcriptome. *Addict Biol* 2017; doi: 10.1111/adb.12501 (e-pub ahead of print).
- 25 Richardson HN, Lee SY, O'Dell LE, Koob GF, Rivier CL. Alcohol self-administration acutely stimulates the hypothalamic-pituitary-adrenal axis, but alcohol dependence leads to a dampened neuroendocrine state. *Eur J Neurosci* 2008; **28**: 1641–1653.
- 26 Vendruscolo LF, Barbier E, Schlosburg JE, Misra KK, Whitfield TW Jr, Logrip ML *et al*. Corticosteroid-dependent plasticity mediates compulsive alcohol drinking in rats. *J Neurosci* 2012; **32**: 7563–7571.
- 27 Addolorato G, Leggio L, Ferrulli A, Cardone S, Bedogni G, Caputo F *et al*. Dose-response effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a Randomized, Double-Blind, Placebo-Controlled Trial. *Alcohol Alcohol* 2011; **46**: 312–317.
- 28 Addolorato G, Leggio L. Safety and efficacy of baclofen in the treatment of alcohol-dependent patients. *Curr Pharm Des* 2010; **16**: 2113–2117.
- 29 Starosta AN, Leeman RF, Volpicelli JR. The BRENDA model: integrating psychosocial treatment and pharmacotherapy for the treatment of alcohol use disorders. *J Psychiatr Pract* 2006; **12**: 80–89.
- 30 Sobell LC, Sobell MB, Leo GI, Cancilla A. Reliability of a Timeline Method: assessing normal drinkers' reports of recent drinking and a comparative evaluation across several populations. *Addiction* 1988; **83**: 393–402.
- 31 Anton RF, Moak DH, Latham P. The Obsessive Compulsive Drinking Scale: a self-rated instrument for the quantification of thoughts about alcohol and drinking behavior. *Alcohol Clin Exp Res* 1995; **19**: 92–99.
- 32 Janiri L, Calvosa F, Dario T, Pozzi G, Ruggeri A, Addolorato G *et al*. The Italian version of the Obsessive–Compulsive Drinking Scale: validation, comparison with the other versions, and difference between type 1- and type 2-like alcoholics. *Drug Alcohol Depend* 2004; **74**: 187–195.
- 33 Spielberger CD, Edwards CD, Montouri J, Lushene R. *Manual for the State and Trait Anxiety Inventory*. Consulting Psychologist Press: Palo Alto, CA, 1983.
- 34 George O, Le Moal M, Koob GF. Allostasis and addiction: Role of the dopamine and corticotropin-releasing factor systems. *Physiol Behav* 2012; **106**: 58–64.
- 35 Vendruscolo LF, Estey D, Goodell V, Macshane LG, Logrip ML, Schlosburg JE *et al*. Glucocorticoid receptor antagonism decreases alcohol seeking in alcohol-dependent individuals. *J Clin Invest* 2015; **125**: 3193–3197.
- 36 Stromstedt M, Waterman MR. Messenger RNAs encoding steroidogenic enzymes are expressed in rodent brain. *Brain Res Mol Brain Res* 1995; **34**: 75–88.
- 37 Gomez-Sanchez CE, Zhou MY, Cozza EN, Morita H, Foecking MF, Gomez-Sanchez EP. Aldosterone biosynthesis in the rat brain. *Endocrinology* 1997; **138**: 3369–3373.
- 38 Gomez-Sanchez EP, Gomez-Sanchez CM, Plonczynski M, Gomez-Sanchez CE. Aldosterone synthesis in the brain contributes to Dahl salt-sensitive rat hypertension. *Exp Physiol* 2010; **95**: 120–130.
- 39 Petropoulos S, Matthews SG, Szyf M. Adult glucocorticoid exposure leads to transcriptional and DNA methylation changes in nuclear steroid receptors in the hippocampus and kidney of mouse male offspring. *Biol Reprod* 2014; **90**: 43.
- 40 Glahn A, Riera Knorrenschild R, Rhein M, Haschemi Nassab M, Groschl M, Heberlein A *et al*. Alcohol-induced changes in methylation status of individual CpG sites, and serum levels of vasopressin and atrial natriuretic peptide in alcohol-dependent patients during detoxification treatment. *Eur Addict Res* 2014; **20**: 143–150.
- 41 Bannan LT, Potter JF, Beevers DG, Saunders JB, Walters JRF, Ingram MC. Effect of alcohol withdrawal on blood pressure, plasma renin activity, aldosterone, cortisol and dopamine β -hydroxylase. *Clin Sci* 1984; **66**: 659–663.
- 42 Bezzegh A, Nyuli L, Kovács GL. α -Atrial natriuretic peptide, aldosterone secretion and plasma renin activity during ethanol withdrawal: a correlation with the onset of delirium tremens? *Alcohol* 1991; **8**: 333–336.
- 43 De Marchi S, Cecchin E, Basile A, Bertotti A, Nardini R, Bartoli E. Renal tubular dysfunction in chronic alcohol abuse—effects of abstinence. *N Engl J Med* 1993; **329**: 1927–1934.
- 44 Regan TJ, Pathan A, Weisse AB, Eaddy C, Torres R. The contribution of arterial pressure to the cardiac dysfunction of chronic alcoholism. *Acta Med Scand* 2009; **218**: 273–280.
- 45 Mander AJ, Weppner GJ, Chick JD, Morton JJ, Best JJ. An NMR study of cerebral oedema and its biological correlates during withdrawal from alcohol. *Alcohol Alcohol* 1988; **23**: 97–102.
- 46 Mander AJ, Young A, MacDonald TM, Williams BC, Waugh CJ, Edwards CR. Blood pressure, renin–angiotensin–aldosterone axis and cortisol changes during withdrawal from alcohol. *Alcohol Alcohol* 1989; **24**: 409–414.
- 47 Vendruscolo LF, Roberts AJ. Operant alcohol self-administration in dependent rats: focus on the vapor model. *Alcohol* 2014; **48**: 277–286.
- 48 Meinhardt MW, Sommer WH. Postdependent state in rats as a model for medication development in alcoholism. *Addict Biol* 2015; **20**: 1–21.
- 49 Beattie MC, Maldonado-Devincini AM, Porcu P, O'Buckley TK, Daunais JB, Grant KA *et al*. Voluntary ethanol consumption reduces GABAergic neuroactive steroid (3 α ,5 α)3-hydroxypregnan-20-one (3 α ,5 α -THP) in the amygdala of the cynomolgus monkey. *Addict Biol* 2015; **22**: 318–330.
- 50 Jimenez VA, Helms CM, Cornea A, Meshul CK, Grant KA. An ultrastructural analysis of the effects of ethanol self-administration on the hypothalamic paraventricular nucleus in rhesus macaques. *Front Cell Neurosci* 2015; **9**: 260.
- 51 Pleil KE, Helms CM, Sobus JR, Daunais JB, Grant KA, Kash TL. Effects of chronic alcohol consumption on neuronal function in the non-human primate BNST. *Addict Biol* 2015; **21**: 1151–1167.
- 52 Bender R, Lange S. Adjusting for multiple testing—when and how? *J Clin Epidemiol* 2001; **54**: 343–349.
- 53 Rothman KJ. No adjustments are needed for multiple comparisons. *Epidemiology* 1990; **1**: 43–46.
- 54 Perneger TV. What's wrong with Bonferroni adjustments. *BMJ* 1998; **316**: 1236–1238.
- 55 Charloux A, Gronfier C, Lonsdorfer-Wolf E, Piquard F, Brandenberger G. Aldosterone release during the sleep–wake cycle in humans. *Am J Physiol* 1999; **276**: E43–E49.



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-nd/4.0/>

© The Author(s) 2018

Supplementary Information accompanies the paper on the Molecular Psychiatry website (<http://www.nature.com/mp>)